{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:57:31Z","timestamp":1788580651224,"version":"build-2803163510"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12325-020-01397-9","type":"journal-article","created":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T15:01:25Z","timestamp":1592233285000},"page":"3040-3058","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?"],"prefix":"10.1007","volume":"37","author":[{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1397_CR1","unstructured":"World Health Organization. Diffuse large B-cell lymphoma. https:\/\/www.who.int\/selection_medicines\/committees\/expert\/20\/applications\/DiffuseLargeBCellLymphoma.pdf. Accessed 4 Apr 2020"},{"issue":"6","key":"1397_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA-Cancer J Clin. 2016;66(6):443\u201359.","journal-title":"CA-Cancer J Clin"},{"key":"1397_CR3","unstructured":"National Cancer Institute. Cancer stat facts: NHL- diffuse large B-call lymphoma (DLBCL). Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html. Accessed 4 Apr 2020."},{"issue":"Suppl 5","key":"1397_CR4","doi-asserted-by":"publisher","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","volume":"26","author":"H Tilly","year":"2015","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v116\u2013v12525.","journal-title":"Ann Oncol."},{"issue":"1","key":"1397_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol-Am Soc Hematol. 2016;2016(1):366\u201378.","journal-title":"Hematol-Am Soc Hematol"},{"key":"1397_CR6","unstructured":"Holmberg LA, Deeg HJ, Sandmaier BM. Determining eligibility for autologous hematopoietic cell transplantation. https:\/\/www.uptodate.com\/contents\/determining-eligibility-for-autologous-hematopoietic-cell-transplantation. Accessed 19 May 2020"},{"issue":"2","key":"1397_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/bmt.2016.213","volume":"52","author":"E Van Den Neste","year":"2017","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study. Bone Marrow Transplant. 2017;52(2):216\u201321.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"1397_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","volume":"51","author":"E Van Den Neste","year":"2016","unstructured":"Van Den Neste E, Schmitz N, Mounier N, Gill D, Linch D, Trneny M, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51\u20137.","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"1397_CR9","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800\u20138.","journal-title":"Blood"},{"issue":"1","key":"1397_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1389201019666180418095526","volume":"19","author":"AN Miliotou","year":"2018","unstructured":"Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5\u201318.","journal-title":"Curr Pharm Biotechnol"},{"issue":"1","key":"1397_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 2019;20(1):31\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1397_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380(1):45\u201356.","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"1397_CR13","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1182\/blood-2019-130983","volume":"134","author":"S Jaglowski","year":"2019","unstructured":"Jaglowski S, Hu Z-H, Zhang Y, Kamdar M, Ghosh M, Lulla P, et al. Tisagenlecleucel chimeric antigen receptor (CAR) T-cell therapy for adults with diffuse large B-cell Lymphoma (DLBCL): Real world experience from the Center for International Blood & Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. Blood. 2019;134(Supplement_1):766.","journal-title":"Blood"},{"issue":"Supplement_1","key":"1397_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1182\/blood-2019-124750","volume":"134","author":"MC Pasquini","year":"2019","unstructured":"Pasquini MC, Locke FL, Herrera AF, Siddiqi T, Ghobadi A, Komanduri KV, et al. Post-marketing use outcomes of an anti-CD10 chimeric antigen receptor (CAR) T cell therapy, axicabtagene ciloleucel (axi-cel), for the treatment of large B cell lymphoma (LBCL) in the United States (US). Blood. 2019;134(Supplement_1):764.","journal-title":"Blood"},{"key":"1397_CR15","doi-asserted-by":"crossref","unstructured":"Riedell PA, Brower J, Nastoupil L, Pennisi M, Maziarz RT, McGuirk JP, et al. A multicenter retrospective analysis of outcomes and toxicities with commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Presented at the Meeting of the American Society for Transplantation and Cellular Therapy on February 19\u201323, 2020, Orlando, FL.","DOI":"10.1016\/j.bbmt.2019.12.108"},{"issue":"Supplement1","key":"1397_CR16","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2019-124177","volume":"134","author":"A Kuhnl","year":"2019","unstructured":"Kuhnl A, Roddie C, Martinez-Cibrian N, Menne TF, Linton K, Lugthart S, et al. Real-world data of high-grade lymphoma patients treated with CD19 CAR-T in England. Blood. 2019;134(Supplement1):767.","journal-title":"Blood"},{"issue":"2","key":"1397_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"key":"1397_CR18","unstructured":"National Institute for Health Care and Excellence (NICE). NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. https:\/\/nicedsu.org.uk\/wp-content\/uploads\/2018\/08\/Population-adjustment-TSD-FINAL-ref-rerun.pdf. Accessed 28 Apr 2020."},{"issue":"1","key":"1397_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.tmrv.2019.08.003","volume":"34","author":"JS Abramson","year":"2020","unstructured":"Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34(1):29\u201333.","journal-title":"Transfus Med Rev"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1182\/blood-2019-129624","volume":"134","author":"M Jain","year":"2019","unstructured":"Jain M, Jacobs M, Nastoupil L, Spiegel J, Feng G, Lin Y, et al. Characteristics and outcomes of patients receiving bridging therapy while awaiting manufacture of standard of care axicabtagene ciloleucel CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed\/refractory large B-cell lymphoma: results from the US lymphoma CAR-T consortium. Blood. 2019;134:245.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR21","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1182\/blood-2019-124492","volume":"134","author":"C Andreadis","year":"2019","unstructured":"Andreadis C, Tam C, Borchmann P, Jaeger U, McGuirk J, Holte H, et al. Correlation of bridging and lymphodepleting chemotherapy with clinical outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma treated with tisagenlecleucel. Blood. 2019;134(Supplement1):2883.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR22","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1182\/blood-2019-131399","volume":"134","author":"SD Nasta","year":"2019","unstructured":"Nasta SD, Hughes M, Namaglu E, Landsburg D, Chong E, Barta S, et al. A characterization of bridging therapies leading up to commerical CAR T-cell therapy. Blood. 2019;134(Supplement1):4108.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR23","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2019-129421","volume":"134","author":"J Paillassa","year":"2019","unstructured":"Paillassa J, Vercellino L, Di Blasi R, Bernard S, Moatti H, Bommier C, et al. Impact of bridging chemotherapy on clinical outcomes of CD19 CAR T therapy in relapse\/refractory diffuse Large B-cell lymphoma in real world experience. Blood. 2019;134(Supplement1):2886.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR24","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2019-131499","volume":"134","author":"C Pinnix","year":"2019","unstructured":"Pinnix C, Gunther J, Dabaja B, Adkins S, Hawkins M, Westin J, et al. Radiation therapy can be an effective bridging strategy prior to axicabtagene ciloleucel therapy for relapsed\/refractory large B-cell lymphoma. Blood. 2019;134(Supplement1):1609.","journal-title":"Blood"},{"key":"1397_CR25","doi-asserted-by":"crossref","unstructured":"Thieblemont C, Le Gouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, et al. Real-world results of an anti-CD19 CAR T-cell axicabtagene ciloleucel for patients with relapsed\/refractory large B-cell lymphoma included in a French early access program. Presented at the 2nd European CAR T Cell Meeting on January 30-February 1, 2020, Sitges, Spain.","DOI":"10.1002\/hon.110_2630"},{"key":"1397_CR26","unstructured":"Kite Pharma Inc. Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V: Axicabtagen-Ciloleucel (YESCARTA) Modul 4A. https:\/\/www.g-ba.de\/downloads\/92-975-2746\/2018-10-31_Modul4A_Axicabtagen-Ciloleucel.pdf. Accessed 13 April 2020."},{"issue":"Supplement1","key":"1397_CR27","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1182\/blood-2018-99-113052","volume":"132","author":"SJ Schuster","year":"2018","unstructured":"Schuster SJ, Maziarz RT, Ericson SG, Rusch ES, Signorovitch J, Romanov VV, et al. Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (r\/r DLBCL) treated with tisagenlecleucel on the JULIET study. Blood. 2018;132(Supplement1):4190.","journal-title":"Blood"},{"issue":"7","key":"1397_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1182\/bloodadvances.2019001304","volume":"4","author":"SJ Schuster","year":"2020","unstructured":"Schuster SJ, Maziarz RT, Rusch ES, Li J, Signorovitch JE, Romanov VV, et al. Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv. 2020;4(7):1432\u20139.","journal-title":"Blood Adv"},{"issue":"6","key":"1397_CR29","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"1397_CR30","unstructured":"Dias S, Welton NJ, Sutton AJ, Ades A. National Institute for Health and Care Excellence (NICE); NICE DSU Technical Support Document 2: A generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310366\/. Accessed 7 Apr 2020."},{"issue":"10","key":"1397_CR31","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"key":"1397_CR32","unstructured":"Alliance for Regenerative Medicine. Getting ready for advanced therapy medicinal products (ATMPs) in Europe. https:\/\/alliancerm.org\/indication-data\/market-access-report\/. Accessed 10 Apr 2020."},{"issue":"10","key":"1397_CR33","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2165\/11537420-000000000-00000","volume":"28","author":"JJ Caro","year":"2010","unstructured":"Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. Pharmacoeconomics. 2010;28(10):957\u201367.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1397_CR34","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40273-015-0271-1","volume":"33","author":"KJ Ishak","year":"2015","unstructured":"Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537\u201349.","journal-title":"Pharmacoeconomics"},{"key":"1397_CR35","unstructured":"National Institute for Health Care and Excellence (NICE). NICE technology appraisal guidance 319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma. https:\/\/www.nice.org.uk\/guidance\/ta319\/resources\/guidance-ipilimumab-for-previously-untreated-advanced-unresectable-or-metastatic-melanoma-pdf. Accessed 10 Apr 2020."},{"key":"1397_CR36","unstructured":"National Institute for Health Care and Excellence (NICE). Talimogene laherparepvec for treating unresectable metastatic melanoma: Technology appraisal guidance [TA410]. https:\/\/www.nice.org.uk\/guidance\/ta410. Accessed 10 Apr 2020."},{"issue":"4","key":"1397_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s12325-016-0313-x","volume":"33","author":"C Quinn","year":"2016","unstructured":"Quinn C, Ma Q, Kudlac A, Palmer S, Barber B, Zhao Z. Indirect treatment comparison of talimogene laherparepvec compared with ipilimumab and vemurafenib for the treatment of patients with metastatic melanoma. Adv Ther. 2016;33(4):643\u201357.","journal-title":"Adv Ther"},{"issue":"2","key":"1397_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12325-016-0464-9","volume":"34","author":"C Quinn","year":"2017","unstructured":"Quinn C, Ma Q, Kudlac A, Palmer S, Barber B, Zhao Z. Relative efficacy of granulocyte-macrophage colony-stimulating factor, dacarbazine, and glycoprotein 100 in metastatic melanoma: an indirect treatment comparison. Adv Ther. 2017;34(2):495\u2013512.","journal-title":"Adv Ther"},{"issue":"Supplement3","key":"1397_CR39","doi-asserted-by":"publisher","first-page":"S522","DOI":"10.1016\/j.jval.2019.09.637","volume":"22","author":"OO Oluwole","year":"2019","unstructured":"Oluwole OO, Jansen J, Lin V, Chan K, Navale L, Locke FL. PCN445 Indirect treatment comparison of axicabtagene ciloleucel (axi-cel) versus tisagenlecleucel (tisa-cel) in relapsed\/refractory large B cell lymphoma (RR-LBCL). Value Health. 2019;22(Supplement3):S522.","journal-title":"Value Health."},{"key":"1397_CR40","unstructured":"United States Food and Drug Administration (FDA). Framework for FDA\u2019s real-world evidence program. https:\/\/www.fda.gov\/media\/120060\/download. Accessed 5 May 2020"},{"issue":"4","key":"1397_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1182\/bloodadvances.2019000952","volume":"4","author":"M Pennisi","year":"2020","unstructured":"Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676\u201386.","journal-title":"Blood Adv"},{"issue":"Supplement1","key":"1397_CR42","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood-2019-129593","volume":"134","author":"A Gajra","year":"2019","unstructured":"Gajra A, Zettler ME, Phillips EG Jr, Klink AJ, Kish JK, Mehta S, et al. Neurological adverse events following CAR-T cell therapy: A real-world analysis of adult patients treated with axicabtagene ciloleucel or tisagenlecleucel. Blood. 2019;134(Supplement1):1952.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR43","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1182\/blood-2019-125769","volume":"134","author":"P Strati","year":"2019","unstructured":"Strati P, Tummala S, Nastoupil LJ, Westin JR, Fayad L, Ahmed S, et al. Clinical and radiological correlates of neurotoxicity after standard of care axicabtagene ciloleucel in patients with relapsed\/refractory large B-cell lymphoma. Blood. 2019;134(Supplement1):765.","journal-title":"Blood"},{"key":"1397_CR44","unstructured":"Iacoboni G, Catala E, Sanchez-Pina J, Bailen R, Mussetti A, Sancho J, et al. Real-world evidence of the use of tisagenlecleucel for patients with relapsed\/refractory aggressive B-cell lymphomas. The Spanish experience. Presented at the 2nd European CAR T Cell Meeting on January 30-February 1, 2020, Sitges, Spain."},{"issue":"Supplement3","key":"1397_CR45","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.1016\/j.bbmt.2019.12.432","volume":"26","author":"N Denlinger","year":"2020","unstructured":"Denlinger N, Braunstein Z, Agyeman A, Purdin Z, Neal A, Yucebay F, et al. CAR T-cell therapy: Clinical outcomes, patient selection and financial metrics with tisagenlecleucel and axicabtagene ciloleucel, a single center experience. Bio Blood Marrow Transplant. 2020;26(Supplement3):S266.","journal-title":"Bio Blood Marrow Transplant."},{"key":"1397_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/hon.110_2630","volume":"37","author":"C Thieblemont","year":"2019","unstructured":"Thieblemont C, Legouill S, Di Blasi R, Cartron G, Morschhauser F, Bachy E, et al. Real-world results on CD19 CAR T-cell for 60 French patients with relapsed\/refractory diffuse large B-cell lymphoma included in a temporary authorization for use program. Hematol Oncol. 2019;37:301.","journal-title":"Hematol Oncol"},{"key":"1397_CR47","doi-asserted-by":"publisher","first-page":"204062071984158","DOI":"10.1177\/2040620719841581","volume":"10","author":"JC Chavez","year":"2019","unstructured":"Chavez JC, Bachmeier C, Kharfan-Dabaja MA. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products. Ther Adv Hematol. 2019;10:2040620719841581.","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"1397_CR48","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1182\/blood-2018-04-839217","volume":"132","author":"VA Chow","year":"2018","unstructured":"Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed\/refractory diffuse large B-cell lymphoma. Blood. 2018;132(8):777\u201381.","journal-title":"Blood"},{"issue":"52","key":"1397_CR49","doi-asserted-by":"publisher","first-page":"29843","DOI":"10.18632\/oncotarget.25688","volume":"9","author":"A Quint\u00e1s-Cardama","year":"2018","unstructured":"Quint\u00e1s-Cardama A. CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma. Oncotarget. 2018;9(52):29843\u20134.","journal-title":"Oncotarget"},{"key":"1397_CR50","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.2147\/CMAR.S163225","volume":"11","author":"A Viardot","year":"2019","unstructured":"Viardot A, Wais V, Sala E, Koerper S. Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of axicabtagene ciloleucel. Cancer Manag Res. 2019;11:2393\u2013404.","journal-title":"Cancer Manag Res"},{"issue":"1","key":"1397_CR51","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S1470-2045(18)30900-8","volume":"20","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ. CD19-directed CAR T cells gain traction. Lancet Oncol. 2019;20(1):2\u20133.","journal-title":"Lancet Oncol"},{"issue":"Supplement1","key":"1397_CR52","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2019-127490","volume":"134","author":"PA Riedell","year":"2019","unstructured":"Riedell PA, Walling C, Nastoupil L, Pennisi M, Maziarz RT, McGuirk JP, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B-cell lymphomas. Blood. 2019;134(Supplement1):1599.","journal-title":"Blood"},{"issue":"Supplement1","key":"1397_CR53","doi-asserted-by":"publisher","first-page":"4108","DOI":"10.1182\/blood-2019-131399","volume":"134","author":"S Dwivedy Nasta","year":"2019","unstructured":"Dwivedy Nasta S, Hughes ME, Namoglu EC, Landsburg DJ, Chong EA, Barta SK, et al. A characterization of bridging therapies leading up to commercial CAR T-cell therapy. Blood. 2019;134(Supplement1):4108.","journal-title":"Blood"},{"key":"1397_CR54","unstructured":"European Society for Blood and Marrow Transplantation. How do I report on patients treated with CAR-T cells to the EBMT Registry? https:\/\/www.ebmt.org\/ebmt\/news\/how-do-i-report-patients-treated-car-t-cells-ebmt-registry. Accessed 28 April 2020."},{"issue":"6","key":"1397_CR55","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S1525-8610(04)70227-3","volume":"2","author":"MR Gillick","year":"2001","unstructured":"Gillick MR. Choosing appropriate medical care for the elderly. J Am Med Dir Assoc. 2001;2(6):305\u20139.","journal-title":"J Am Med Dir Assoc"},{"issue":"8","key":"1397_CR56","first-page":"379","volume":"25","author":"J Thornton Snider","year":"2019","unstructured":"Thornton Snider J, Brauer M, Kee R, Batt K, Karaca-Mandic P, Zhang J, et al. The potential impact of CAR T-cell treatment delays on society. Am J Manag Care. 2019;25(8):379\u201386.","journal-title":"Am J Manag Care"},{"key":"1397_CR57","unstructured":"American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE). Patient access to necessary and appropriate medical care. https:\/\/www.empoweryourhealth.org\/magazine\/vol9_issue2\/patient_access_to_necessary_and_appropriate_medical_care. Accessed 7 Apr 2020."},{"key":"1397_CR58","unstructured":"National Pharmaceutical Council. Patient access to medicines: A growing challenge. https:\/\/www.npcnow.org\/newsletter\/content\/patient-access-medicines-growing-challenge. Accessed 7 Apr 2020."},{"key":"1397_CR59","unstructured":"Office of Disease Prevention and Health Promotion (ODPHP). Access to health services. https:\/\/www.healthypeople.gov\/2020\/topics-objectives\/topic\/Access-to-Health-Services. Accessed 7 Apr 2020."},{"key":"1397_CR60","unstructured":"Institute of Medicine (US) Committee on Monitoring Access to Personal Health Care Services. Access to Health Care in America. Millman M, editor. Washington (DC): National Academies Press (US); 1993."},{"key":"1397_CR61","unstructured":"Franco E. Navigating patient access in the new age of health care. https:\/\/www.nthrive.com\/blog\/navigating-patient-access-in-the-new-age-of-health-care. Accessed 7 Apr 2020."},{"issue":"6","key":"1397_CR62","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","volume":"100","author":"OG Ottmann","year":"2002","unstructured":"Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100(6):1965\u201371.","journal-title":"Blood"},{"issue":"36","key":"1397_CR63","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol. 2014;32(36):4134\u201340.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1397_CR64","doi-asserted-by":"publisher","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","volume":"109","author":"DJ DeAngelo","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT, et al. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: cancer and Leukemia Group B study 19801. Blood. 2007;109(12):5136\u201342.","journal-title":"Blood"},{"issue":"12","key":"1397_CR65","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1200\/JCO.2005.03.8554","volume":"24","author":"S Jeha","year":"2006","unstructured":"Jeha S, Gaynon PS, Razzouk BI, Franklin J, Kadota R, Shen V, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol. 2006;24(12):1917\u201323.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1397_CR66","doi-asserted-by":"publisher","first-page":"A558","DOI":"10.1016\/j.jval.2015.09.1808","volume":"18","author":"S Langham","year":"2015","unstructured":"Langham S, Pooley N, Madrigal AM. The challenges of carrying out an indirect comparison with single-arm studies. Value Health. 2015;18(7):A558.","journal-title":"Value Health"},{"issue":"9","key":"1397_CR67","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/pds.4297","volume":"26","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1397_CR68","unstructured":"National Institute for Health Care and Excellence (NICE), Bell H, Wailoo AJ, Hernandez M, Grieve R, Faria R, et al. The use of real world data for the estimation of treatment effects in NICE decision making. Report by the decision support unit. https:\/\/nicedsu.org.uk\/wp-content\/uploads\/2018\/05\/RWD-DSU-REPORT-Updated-DECEMBER-2016.pdf. Accessed 5 May 2020"},{"key":"1397_CR69","unstructured":"National Institute for Health Care and Excellence (NICE), Faria R, Hernadez Alava M, Manca A, Wailoo AJ. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. https:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/TSD17-DSU-Observational-data-FINAL.pdf. Accessed 5 May 2020"},{"key":"1397_CR70","unstructured":"European Agency for the Evaluation of Medicinal Products. ICH topic E10\u2014Choice of control group in clinical trials. Note for guidance on choice of control group in clinical trials. (CPMP\/ICH\/364\/96). Presented at International Conference on Harmonization on July 27, 2000 at London, United Kingdom."},{"issue":"1","key":"1397_CR71","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.therap.2019.11.007","volume":"75","author":"M Cucherat","year":"2020","unstructured":"Cucherat M, Laporte S, Delaitre O, Behier J-M, d\u2019Andon A, Binlich F, et al. From single-arm studies to externally controlled studies Methodological considerations and guidelines. Therapies. 2020;75(1):21\u20137.","journal-title":"Therapies"},{"key":"1397_CR72","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Auf den Punkt gerbracht. https:\/\/www.iqwig.de\/download\/2016_IQWiG_Auf_den_Punkt_gebracht.pdf. Accessed 28 Apr 28 2020"},{"issue":"47","key":"1397_CR73","first-page":"803","volume":"112","author":"C Kiefer","year":"2015","unstructured":"Kiefer C, Sturtz S, Bender R. Indirect comparisons and network meta-analyses. Dtsch Arztebl Int. 2015;112(47):803\u20138.","journal-title":"Dtsch Arztebl Int"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01397-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01397-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T11:22:51Z","timestamp":1696245771000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01397-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":73,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01397-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}